JD

Jose Daisy

Active Director Director DIN 02692589
DIN 02692589 First appointment Jul 2009 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2009
Shareholding value •••• Premium profile

About Jose Daisy

Data last updated:

Jose Daisy is a Director at Kannikkatt Pharmaceuticals Private Limited (since 2009). The company operates in Pharma. Kannikkatt Pharmaceuticals Private Limited reported revenue of ₹26.1 Lakh (FY 2026).

DIN 02692589
Primary Designation Director
Industry Pharma
First Appointment 29 Jul 2009
Oldest Company Age 30 yrs
Largest company Kannikkatt Pharmaceuticals Private Limited · ₹26.1 Lakh (FY 2026)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Jul 20091996₹26.1 Lakh (FY 2026)Active

Board colleagues of Jose Daisy

Directorship timeline

Open interactive timeline →
Kannikkatt Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Jose Daisy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jose Daisy

Jose Daisy currently holds 1 directorship: Kannikkatt Pharmaceuticals Private Limited (Director, since 29 Jul 2009, revenue ₹26.1 Lakh (FY 2026)).

Jose Daisy was first appointed on 29 Jul 2009 as Director at Kannikkatt Pharmaceuticals Private Limited.

The current boards of Jose Daisy's companies include Alka Jose (Kannikkatt Pharmaceuticals Private Limited), Kannikkat Mathew Jose (Kannikkatt Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available